Authors
Latest:
Dr. Sanft on Sequencing of Treatments for HER2+ Breast CancerTara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.
Latest:
Dr. King on Neoadjuvant Chemotherapy in Breast CancerTari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.
Latest:
Dr Feldman on the Importance of the TRANSCEND CLL 004 Trial in CLL/SLLTatyana Feldman, MD, discusses the TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
Latest:
Dr. Turner on Important Steps for Genomic Profiling in Gynecologic MalignanciesTaylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.
Latest:
There and Back…One of my teachers in medical school was fond of saying, "Internal medicine isn't sexy." Hematology/ oncology is no exception to this rule. Certainly, it is not as glamorous as cardiology or as hands-on as gastroenterology.
Latest:
Ted Okon Foresees a Shortage of Oncologists in the FutureTed Okon Explains Why he Foresees a Shortage of Oncologists in the Future
Latest:
Organization Rallies Global Oncology Community to Eliminate Cancer Health DisparitiesToday, more than half of new cancer cases and over two-thirds of cancer deaths occur in low- and middle-income countries.
Latest:
Dr Friedlander on the Design and Methods of the Duravelo-2 Trial in Urothelial CancerTerence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.
Latest:
Dr. Williams on NLR as a Prognostic Biomarker in NSCLCTerence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.
Latest:
Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLCTerence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.
Latest:
Dr. Woodruff on Oncofertility Insurance CoverageDr. Teresa Woodruff from Feinberg School of Medicine, Northwestern University, Discusses Oncofertility Insurance Coverage
Latest:
Dr. Macarulla Discusses Rapid Progressors in the POLO TrialTeresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.
Latest:
Dr. Bradley on the Utility of Ruxolitinib in Myelofibrosis and Polycythemia VeraTerrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.
Latest:
Five Steps to Financial Security for FellowsThe first few years after medical school can seem financially suffocating for young physicians.
Latest:
Dr. Terri Febbraro on the Inverse Correlation Between Time on Chemotherapy and OSTerri Febbraro, MD, third year fellow, University of Chicago/NorthShore University Health System, discusses length of time receiving chemotherapy versus overall survival in patients with ovarian cancer. Febbraro says the study looked at three separate groups of patients with ovarian cancer based on the length of time they receieved chemotherapy, with the group being on chemotherapy the longest having the worst overall survival rates.
Latest:
Dr. Terri Woodard on Preservative Measures for Women With Ovarian CancerTerri Woodard, MD, assistant professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses if conservative management for women with ovarian cancer is warranted.
Latest:
Plans to Implement Fee-for-Value Models in OncologyTerrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.
Latest:
Incorporating Precision Medicine into OncologyTerrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.
Latest:
Dr. Evans on the Tolerability of CDK4/6 Inhibitors in HR+ Breast CancerTerry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.
Latest:
New Frontier for Genomics: Radiotherapy in Early Breast CancerBy individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.
Latest:
Dr. Mamounas on the Role of Extended Adjuvant Endocrine Therapy in ER+ Breast CancerEleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.
Latest:
US Oncology Network Continues Its Rapid Growth and Enhances Surgical ExpertiseThe US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists, a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network.
Latest:
Dr. Ho on First-Line TKI Monotherapy in mRCCThai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.
